This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD. This FOA invites Stage 0 (basic research) or Stage I (intervention development/modification) clinical trials, in line with the NIH Stage Model.
Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-18-582, which uses the exploratory/developmental (R21) grant mechanism.
PAR-18-581 Expiration Date June 9, 2020
